CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy

Mustafa Nissar Bankur; Archie Keeling; Khoodoruth Mohamed Adil Shah; Daniele Avenoso

doi:10.3390/hematolrep14030029

CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy

Hematol Rep. 2022 Jun 23;14(3):213-221. doi: 10.3390/hematolrep14030029.

Authors

Mustafa Nissar Bankur^{1

2}, Archie Keeling³, Khoodoruth Mohamed Adil Shah⁴, Daniele Avenoso¹

Affiliations

¹ Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
² Neurosciences Department, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
³ Radiology Department, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
⁴ Department of Psychiatry, Hamad Medical Corporation, Doha 00000, Qatar.

Abstract

Herein, we present a case of cytomegalovirus (CMV) colitis that occurred after two cycles of azacitidine and venetoclax in a 64-year-old woman affected with acute myeloid leukaemia (AML) secondary to a previous diagnosis of a hypoplastic myelodysplastic syndrome (hypo-MDS). This patient never had detectable CMV viraemia, and there was no evidence of immune deficiency that could justify this opportunistic infection. Additionally, this is most likely the first report describing CMV colitis in a patient treated upfront with azacitidine and venetoclax.

Keywords: AML; CMV; venetoclax.

Publication types

Case Reports

Grants and funding

This research received no external funding.